Molecular Analyses of Malignant Pleural Mesothelioma

Total Page:16

File Type:pdf, Size:1020Kb

Molecular Analyses of Malignant Pleural Mesothelioma Molecular Analyses of Malignant Pleural Mesothelioma Shir Kiong Lo National Heart and Lung Institute Imperial College Dovehouse Street London SW3 6LY A thesis submitted for MD (Res) Faculty of Medicine, Imperial College London 2016 1 Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer that is strongly associated with asbestos exposure. Majority of patients with MPM present with advanced disease and the treatment paradigm mainly involves palliative chemotherapy and best supportive care. The current chemotherapy options are limited and ineffective hence there is an urgent need to improve patient outcomes. This requires better understanding of the genetic alterations driving MPM to improve diagnostic, prognostic and therapeutic strategies. This research aims to gain further insights in the pathogenesis of MPM by exploring the tumour transcriptional and mutational profiles. We compared gene expression profiles of 25 MPM tumours and 5 non-malignant pleura. This revealed differentially expressed genes involved in cell migration, invasion, cell cycle and the immune system that contribute to the malignant phenotype of MPM. We then constructed MPM-associated co-expression networks using weighted gene correlation network analysis to identify clusters of highly correlated genes. These identified three distinct molecular subtypes of MPM associated with genes involved in WNT and TGF-ß signalling pathways. Our results also revealed genes involved in cell cycle control especially the mitotic phase correlated significantly with poor prognosis. Through exome analysis of seven paired tumour/blood and 29 tumour samples, we identified frequent mutations in BAP1 and NF2. Additionally, the mutational profile of MPM is enriched with genes encoding FAK, MAPK and WNT signalling pathways. We also found mutations in several novel genes involved in chromatin remodelling other than BAP1 and SETD2 that may contribute to dysregulation of gene expression in MPM. In conclusion, MPM is a complex disease with heterogeneous molecular aberrations. By combining findings from both transcriptome and exome analyses, we identified alterations in genes involved in common signalling pathways such as FAK, WNT and MAPK. These may have important roles in driving MPM carcinogenesis with therapeutic implications and require further explorations. 2 Abbreviations Abbreviations Full name BAM Binary Alignment Map bp base pairs BRC Biomedical Research Centre BRU Biomedical Research Units CALBG Cancer and Leukaemia Group B CDK Cyclin Dependent Kinases cDNA complementary Deoxyribonucleic Acid CEA Carcinoembryonic Antigen CL4 Claudin-4 COSMIC Catalogue of Somatic Mutations in Cancer CRL4 Cullin4A-RING E3 ubiquitin Ligase cRNA complementary Ribonucleic Acid CSC Cancer Stem Cells CT Computed Tomography CTLA-4 Cytotoxic T Lymphocyte Antigen-4 DM Data Mining DNA Deoxyribonucleic Acid DNMTi DNA Methyltransferase inhibitor dNTP deoxyribonucleotide triphosphate ECM Extracellular Matrix EGFR Epidermal Growth Factor Receptor EMA Epithelial Membrane Antigen EMT Epithelial-Mesenchymal Transition EORTC European Organisation for Research and Treatment of Cancer EPP Extra-Pleural Pneumonectomy ERK Extracellular-signal-Regulated Kinases ExAC Exome Aggregation Consortium FAK Focal Adhesion Kinase FC Fold Change FDR False Discovery Rate FFPE Formalin- Fixed, Paraffin-Embedded gm Grams GO Gene Ontology GS Gene Significance GWAS Genome-wide association study GWAS Genome-Wide Association Study H&E Haematoxylin and Eosin HA Hyaluronate HCA Hierarchical Clustering Algorithm 3 HDACi Histone Deacetylase Inhibitors HGF Hepatocyte Growth Factor HMGB1 High Molecular Group Binding Protein 1 IASLC International Association for the Study of Lung Cancer IGF1 Insulin Growth Factor 1 IHC Immunohistochemistry IMIG International Mesothelioma Interest Group indels insertions/deletions IVT in vitro Transcription KEGG Kyoto Encyclopaedia of Genes and Genomes LCM Laser-Capture Micro-dissection LRP Lipoprotein-Related Protein MAPK Mitogen-Activated Protein Kinases MEMO Molecular Analyses of Malignant Pleural Mesothelioma MEs Module Eigengenes MET MET Proto-oncogene MHC Major Histocompatibility Complex miR micro RNA ml Millilitre MM Module Membership MPM Malignant Pleural Mesothelioma MSAC Mitotic Spindle and Assembly Checkpoint mTOR Mammalian Target of Rapamycin NER Nucleotide Excision Repair NF-κB Nuclear Factor Kappa-light-chain-enhancer of activated B cells ng Nanogram NGS Next Generation Sequencing NIHR National Institute for Health Research NK Natural Killer nt Nucleotides OCT Optimal Cutting Temperature OS Overall Survival PCA Principal Component Analysis PCR Polymerase Chain Reaction PD-1 Programmed Death-1 PDP Podoplanin PEN Polyethylene Napthalate PFS Progression-Free Survival PI3K Phosphoinositide 3-Kinase PM Perfect Match PVCA Principal Variance Component Analysis RBH Royal Brompton and Harefield NHS Foundation Trust Hospital RIN RNA Integrity Number RMA Random Multiple Access RMH Royal Marsden NHS Foundation Trust Hospital 4 RNA Ribonucleic Acid RTK Receptor Tyrosine Kinase RTS Review on Transcriptome Studies SGH St George’s Hospital SHH Sonic Hedgehog siRNA small interfering RNA SMRP Soluble Mesothelin-Related Peptides SNP single Nucleotide Polymorphisms SNV Single Nucleotide Variants SV40 Simian Virus 40 TGF-ß1 Transforming Growth Factor Beta 1 TNF Tumour Necrosis Factor TOM Topological Overlap Matrix TSG Tumour Suppressor Gene TUCP Transcripts of Uncertain Coding Potential UK United Kingdom USA United States of America UV Ultraviolet VCF Varian Call Format WES Whole Exome Sequencing WGCNA Weighted Gene Co-expression Network Analysis WHO World Health Organisation WT1 Wilms’ Tumor-1 protein µg Microgram µl Microliter µm Micrometre 5 Acknowledgements Firstly, I would like to express my sincere gratitude to both my supervisors, Professor Cookson and Dr Popat, for giving me this invaluable opportunity to conduct this research. I am extremely grateful for their guidance, motivation and patience. My sincere thanks also go to Professor Moffatt and Professor Bowcock for their insightful advice and encouragement. I am also very grateful to the immense input from Professor Lathrop, Professor Nicholson, Dr Montero and their team. I would also like to thank the Brunei Government and Lung Unit, Royal Marsden Hospital that funded me to study at the National Heart and Lung Institute, Imperial College. I would also like to acknowledge all the members of the Molecular Genetics & Genomics and Cancer Genomics group in particularly Liz, Hima, Saffron, Youming, Kenny and Spyros for their help and advice throughout my research. Lastly, I would like to thank my family and friends who are always there for me. 6 Declaration of Originality I herewith certify that this dissertation is my original work and that all materials included which are not my own work have been acknowledged. 7 Copyright Declaration The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or transmit the thesis on the condition that they attribute it, that they do not use it for commercial purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, researchers must make clear to others the licence terms of this work. 8 Table of Contents Abstract .................................................................................................................................................................. 2 Abbreviations ........................................................................................................................................................ 3 Acknowledgements................................................................................................................................................ 6 Declaration of Originality..................................................................................................................................... 7 Copyright Declaration .......................................................................................................................................... 8 Chapter 1 - Introduction .................................................................................................................................... 15 1.1 Background.......................................................................................................................................... 15 1.2 Mesothelial cells and the pleura .......................................................................................................... 17 1.3 Epidemiology ...................................................................................................................................... 19 1.4 Risk factors .......................................................................................................................................... 21 1.4.1 Asbestos ...................................................................................................................................... 21 1.4.2 Other risk factors including genetic susceptibility ...................................................................... 24 1.5 Diagnostic biomarkers ......................................................................................................................... 28 1.6 Molecular changes in MPM ...............................................................................................................
Recommended publications
  • ENSG Gene Encodes Effector TCR Pathway Costimulation Inhibitory/Exhaustion Synapse/Adhesion Chemokines/Receptors
    ENSG Gene Encodes Effector TCR pathway Costimulation Inhibitory/exhaustion Synapse/adhesion Chemokines/receptors ENSG00000111537 IFNG IFNg x ENSG00000109471 IL2 IL-2 x ENSG00000232810 TNF TNFa x ENSG00000271503 CCL5 CCL5 x x ENSG00000139187 KLRG1 Klrg1 x ENSG00000117560 FASLG Fas ligand x ENSG00000121858 TNFSF10 TRAIL x ENSG00000134545 KLRC1 Klrc1 / NKG2A x ENSG00000213809 KLRK1 Klrk1 / NKG2D x ENSG00000188389 PDCD1 PD-1 x x ENSG00000117281 CD160 CD160 x x ENSG00000134460 IL2RA IL-2 receptor x subunit alpha ENSG00000110324 IL10RA IL-10 receptor x subunit alpha ENSG00000115604 IL18R1 IL-18 receptor 1 x ENSG00000115607 IL18RAP IL-18 receptor x accessory protein ENSG00000081985 IL12RB2 IL-12 receptor x beta 2 ENSG00000186810 CXCR3 CXCR3 x x ENSG00000005844 ITGAL CD11a x ENSG00000160255 ITGB2 CD18; Integrin x x beta-2 ENSG00000156886 ITGAD CD11d x ENSG00000140678 ITGAX; CD11c x x Integrin alpha-X ENSG00000115232 ITGA4 CD49d; Integrin x x alpha-4 ENSG00000169896 ITGAM CD11b; Integrin x x alpha-M ENSG00000138378 STAT4 Stat4 x ENSG00000115415 STAT1 Stat1 x ENSG00000170581 STAT2 Stat2 x ENSG00000126561 STAT5a Stat5a x ENSG00000162434 JAK1 Jak1 x ENSG00000100453 GZMB Granzyme B x ENSG00000145649 GZMA Granzyme A x ENSG00000180644 PRF1 Perforin 1 x ENSG00000115523 GNLY Granulysin x ENSG00000100450 GZMH Granzyme H x ENSG00000113088 GZMK Granzyme K x ENSG00000057657 PRDM1 Blimp-1 x ENSG00000073861 TBX21 T-bet x ENSG00000115738 ID2 ID2 x ENSG00000176083 ZNF683 Hobit x ENSG00000137265 IRF4 Interferon x regulatory factor 4 ENSG00000140968 IRF8 Interferon
    [Show full text]
  • Ejercicio Físico En La Patogenia De La Artritis Inducida Por Proteoglicano En Ratón
    UNIVERSIDAD AUTÓNOMA DE CHIHUAHUA FACULTAD DE CIENCIAS DE LA CULTURA FÍSICA SECRETARÍA DE INVESTIGACIÓN Y POSGRADO EJERCICIO FÍSICO EN LA PATOGENIA DE LA ARTRITIS INDUCIDA POR PROTEOGLICANO EN RATÓN TESIS QUE PARA OBTENER EL GRADO DE: DOCTORA EN CIENCIAS DE LA CULTURA FÍSICA PRESENTA: M. EN C. SUSANA AIDEÉ GONZÁLEZ CHÁVEZ DIRECTOR DE TESIS: DR. CÉSAR FRANCISCO PACHECO TENA CHIHUAHUA, CHIH., MÉXICO, SEPTIEMBRE DE 2017 UNIVERSIDAD AUTÓNOMA DE CHIHUAHUA FACULTAD DE CIENCIAS DE LA CULTURA FÍSICA SECRETARÍA DE INVESTIGACIÓN Y POSGRADO El que suscribe, integrante del Núcleo Complementario del Programa de Doctorado Interinstitucional en Ciencias de la Cultura Física de la Facultad de Ciencias de la Cultura Física de la Universidad Autónoma de Chihuahua. CERTIFICA Que el presente trabajo titulado “Ejercicio físico en la patogenia de la artritis inducida por proteoglicano en ratón”, ha sido realizado bajo mi dirección en el Laboratorio de Investigación PABIOM de la Facultad de Medicina y Ciencias Biomédicas de la Universidad Autónoma de Chihuahua, por la M. en C. Susana Aideé González Chávez para optar por el grado de: DOCTORA EN CIENCIAS DE LA CULTURA FÍSICA Esta es una investigación original que ha sido realizada con rigor ético y científico, por lo que autorizo su presentación ante el grupo de sinodales correspondiente. Para los fines que haya lugar, se extiende la presente a los doce días del mes de Septiembre del dos mil diecisiete. Atentamente Dr. César Francisco Pacheco Tena Doctor en Ciencias Médicas Facultad de Medicina y Ciencias Biomédicas, UACH i UNIVERSIDAD AUTÓNOMA DE CHIHUAHUA FACULTAD DE CIENCIAS DE LA CULTURA FÍSICA SECRETARÍA DE INVESTIGACIÓN Y POSGRADO El presente trabajo “Ejercicio físico en la patogenia de la artritis inducida por proteoglicano en ratón” realizado por la M.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • 3034.Full.Pdf
    Characterization of the CD200 Receptor Family in Mice and Humans and Their Interactions with CD200 This information is current as Gavin J. Wright, Holly Cherwinski, Mildred Foster-Cuevas, of September 28, 2021. Gary Brooke, Michael J. Puklavec, Mike Bigler, Yaoli Song, Maria Jenmalm, Dan Gorman, Terri McClanahan, Man-Ru Liu, Marion H. Brown, Jonathon D. Sedgwick, Joseph H. Phillips and A. Neil Barclay J Immunol 2003; 171:3034-3046; ; Downloaded from doi: 10.4049/jimmunol.171.6.3034 http://www.jimmunol.org/content/171/6/3034 References This article cites 39 articles, 20 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/171/6/3034.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 28, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Characterization of the CD200 Receptor Family in Mice and Humans and Their Interactions with CD2001 Gavin J.
    [Show full text]
  • Regulation of Cdc42 and Its Effectors in Epithelial Morphogenesis Franck Pichaud1,2,*, Rhian F
    © 2019. Published by The Company of Biologists Ltd | Journal of Cell Science (2019) 132, jcs217869. doi:10.1242/jcs.217869 REVIEW SUBJECT COLLECTION: ADHESION Regulation of Cdc42 and its effectors in epithelial morphogenesis Franck Pichaud1,2,*, Rhian F. Walther1 and Francisca Nunes de Almeida1 ABSTRACT An overview of Cdc42 Cdc42 – a member of the small Rho GTPase family – regulates cell Cdc42 was discovered in yeast and belongs to a large family of small – polarity across organisms from yeast to humans. It is an essential (20 30 kDa) GTP-binding proteins (Adams et al., 1990; Johnson regulator of polarized morphogenesis in epithelial cells, through and Pringle, 1990). It is part of the Ras-homologous Rho subfamily coordination of apical membrane morphogenesis, lumen formation and of GTPases, of which there are 20 members in humans, including junction maturation. In parallel, work in yeast and Caenorhabditis elegans the RhoA and Rac GTPases, (Hall, 2012). Rho, Rac and Cdc42 has provided important clues as to how this molecular switch can homologues are found in all eukaryotes, except for plants, which do generate and regulate polarity through localized activation or inhibition, not have a clear homologue for Cdc42. Together, the function of and cytoskeleton regulation. Recent studies have revealed how Rho GTPases influences most, if not all, cellular processes. important and complex these regulations can be during epithelial In the early 1990s, seminal work from Alan Hall and his morphogenesis. This complexity is mirrored by the fact that Cdc42 can collaborators identified Rho, Rac and Cdc42 as main regulators of exert its function through many effector proteins.
    [Show full text]
  • A Genome-Wide Association Study Lystra P
    Hayden et al. Respiratory Research (2018) 19:209 https://doi.org/10.1186/s12931-018-0890-0 RESEARCH Open Access Childhood asthma is associated with COPD and known asthma variants in COPDGene: a genome-wide association study Lystra P. Hayden1,2* , Michael H. Cho2,3, Benjamin A. Raby1,2,3, Terri H. Beaty4, Edwin K. Silverman2,3, Craig P. Hersh2,3 and on behalf of the COPDGene Investigators Abstract Background: Childhood asthma is strongly influenced by genetics and is a risk factor for reduced lung function and chronic obstructive pulmonary disease (COPD) in adults. This study investigates self-reported childhood asthma in adult smokers from the COPDGene Study. We hypothesize that childhood asthma is associated with decreased lung function, increased risk for COPD, and that a genome-wide association study (GWAS) will show association with established asthma variants. Methods: We evaluated current and former smokers ages 45–80 of non-Hispanic white (NHW) or African American (AA) race. Childhood asthma was defined by self-report of asthma, diagnosed by a medical professional, with onset at < 16 years or during childhood. Subjects with a history of childhood asthma were compared to those who never had asthma based on lung function, development of COPD, and genetic variation. GWAS was performed in NHW and AA populations, and combined in meta-analysis. Two sets of established asthma SNPs from published literature were examined for association with childhood asthma. Results: Among 10,199 adult smokers, 730 (7%) reported childhood asthma and 7493 (73%) reported no history of asthma. Childhood asthmatics had reduced lung function and increased risk for COPD (OR 3.42, 95% CI 2.81–4.18).
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • CD200 and Its Receptor, CD200R, Modulate Bone Mass Via the Differentiation of Osteoclasts
    CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts Weiguo Cui*†, Esteban Cuartas*, Juan Ke*‡, Qing Zhang*, Halldor B. Einarsson*, Jonathon D. Sedgwick§¶, Jun Liʈ, and Agne` s Vignery*,** *Department of Orthopedics and Rehabilitation, Yale School of Medicine, 310 Cedar Street, New Haven, CT 06510; §Schering–Plough Biopharma (DNAX), Palo Alto, CA 94304; and ʈDepartment of Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 Edited by Richard A. Flavell, Yale University School of Medicine, New Haven, CT, and approved July 25, 2007 (received for review April 11, 2007) Fusion of macrophages is an essential step in the differentiation of plays a role in the recognition of self and in the fusion of macro- osteoclasts, which play a central role in the development and remod- phages (10). To gain further insight into the mechanism of mac- eling of bone. Osteoclasts are important mediators of bone loss, rophage fusion, we subjected fusing alveolar macrophages from rats which leads, for example, to osteoporosis. Macrophage fusion recep- to genome-wide oligonucleotide microarray analysis, and we dis- tor/signal regulatory protein ␣ (MFR/SIRP␣) and its ligand CD47, covered the expression of CD200 de novo at the onset of fusion. which are members of the Ig superfamily (IgSF), have been implicated CD200 also belongs to the IgSF and has a short cytoplasmic tail. in the fusion of macrophages. We show that CD200, which is not It is expressed on various types of mouse and human cells (see ref. expressed in cells that belong to the myeloid lineage, is strongly 11 for a review) and on mouse osteoblasts (12), but not on expressed in macrophages at the onset of fusion.
    [Show full text]
  • Ageing-Associated Changes in DNA Methylation in X and Y Chromosomes
    Kananen and Marttila Epigenetics & Chromatin (2021) 14:33 Epigenetics & Chromatin https://doi.org/10.1186/s13072-021-00407-6 RESEARCH Open Access Ageing-associated changes in DNA methylation in X and Y chromosomes Laura Kananen1,2,3,4* and Saara Marttila4,5* Abstract Background: Ageing displays clear sexual dimorphism, evident in both morbidity and mortality. Ageing is also asso- ciated with changes in DNA methylation, but very little focus has been on the sex chromosomes, potential biological contributors to the observed sexual dimorphism. Here, we sought to identify DNA methylation changes associated with ageing in the Y and X chromosomes, by utilizing datasets available in data repositories, comprising in total of 1240 males and 1191 females, aged 14–92 years. Results: In total, we identifed 46 age-associated CpG sites in the male Y, 1327 age-associated CpG sites in the male X, and 325 age-associated CpG sites in the female X. The X chromosomal age-associated CpGs showed signifcant overlap between females and males, with 122 CpGs identifed as age-associated in both sexes. Age-associated X chro- mosomal CpGs in both sexes were enriched in CpG islands and depleted from gene bodies and showed no strong trend towards hypermethylation nor hypomethylation. In contrast, the Y chromosomal age-associated CpGs were enriched in gene bodies, and showed a clear trend towards hypermethylation with age. Conclusions: Signifcant overlap in X chromosomal age-associated CpGs identifed in males and females and their shared features suggest that despite the uneven chromosomal dosage, diferences in ageing-associated DNA methylation changes in the X chromosome are unlikely to be a major contributor of sex dimorphism in ageing.
    [Show full text]
  • Tepzz¥ 6Z54za T
    (19) TZZ¥ ZZ_T (11) EP 3 260 540 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.12.2017 Bulletin 2017/52 C12N 15/113 (2010.01) A61K 9/127 (2006.01) A61K 31/713 (2006.01) C12Q 1/68 (2006.01) (21) Application number: 17000579.7 (22) Date of filing: 12.11.2011 (84) Designated Contracting States: • Sarma, Kavitha AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Philadelphia, PA 19146 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Borowsky, Mark PL PT RO RS SE SI SK SM TR Needham, MA 02494 (US) • Ohsumi, Toshiro Kendrick (30) Priority: 12.11.2010 US 412862 P Cambridge, MA 02141 (US) 20.12.2010 US 201061425174 P 28.07.2011 US 201161512754 P (74) Representative: Clegg, Richard Ian et al Mewburn Ellis LLP (62) Document number(s) of the earlier application(s) in City Tower accordance with Art. 76 EPC: 40 Basinghall Street 11840099.3 / 2 638 163 London EC2V 5DE (GB) (71) Applicant: The General Hospital Corporation Remarks: Boston, MA 02114 (US) •Thecomplete document including Reference Tables and the Sequence Listing can be downloaded from (72) Inventors: the EPO website • Lee, Jeannie T •This application was filed on 05-04-2017 as a Boston, MA 02114 (US) divisional application to the application mentioned • Zhao, Jing under INID code 62. San Diego, CA 92122 (US) •Claims filed after the date of receipt of the divisional application (Rule 68(4) EPC). (54) POLYCOMB-ASSOCIATED NON-CODING RNAS (57) This invention relates to long non-coding RNAs (IncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting IncRNAs.
    [Show full text]
  • Identification of Tumor-Associated Cassette Exons in Human Cancer
    Valletti et al. Molecular Cancer 2010, 9:230 http://www.molecular-cancer.com/content/9/1/230 RESEARCH Open Access Identification of tumor-associated cassette exons in human cancer through EST-based computational prediction and experimental validation Alessio Valletti1†, Anna Anselmo2†, Marina Mangiulli1, Ilenia Boria1, Flavio Mignone3, Giuseppe Merla4, Vincenzo D’Angelo5, Apollonia Tullo6, Elisabetta Sbisà6, Anna Maria D’Erchia1, Graziano Pesole1,7* Abstract Background: Many evidences report that alternative splicing, the mechanism which produces mRNAs and proteins with different structures and functions from the same gene, is altered in cancer cells. Thus, the identification and characterization of cancer-specific splice variants may give large impulse to the discovery of novel diagnostic and prognostic tumour biomarkers, as well as of new targets for more selective and effective therapies. Results: We present here a genome-wide analysis of the alternative splicing pattern of human genes through a computational analysis of normal and cancer-specific ESTs from seventeen anatomical groups, using data available in AspicDB, a database resource for the analysis of alternative splicing in human. By using a statistical methodology, normal and cancer-specific genes, splice sites and cassette exons were predicted in silico. The condition association of some of the novel normal/tumoral cassette exons was experimentally verified by RT-qPCR assays in the same anatomical system where they were predicted. Remarkably, the presence in vivo of the predicted alternative transcripts, specific for the nervous system, was confirmed in patients affected by glioblastoma. Conclusion: This study presents a novel computational methodology for the identification of tumor-associated transcript variants to be used as cancer molecular biomarkers, provides its experimental validation, and reports specific biomarkers for glioblastoma.
    [Show full text]
  • Plenary and Platform Abstracts
    American Society of Human Genetics 68th Annual Meeting PLENARY AND PLATFORM ABSTRACTS Abstract #'s Tuesday, October 16, 5:30-6:50 pm: 4. Featured Plenary Abstract Session I Hall C #1-#4 Wednesday, October 17, 9:00-10:00 am, Concurrent Platform Session A: 6. Variant Insights from Large Population Datasets Ballroom 20A #5-#8 7. GWAS in Combined Cancer Phenotypes Ballroom 20BC #9-#12 8. Genome-wide Epigenomics and Non-coding Variants Ballroom 20D #13-#16 9. Clonal Mosaicism in Cancer, Alzheimer's Disease, and Healthy Room 6A #17-#20 Tissue 10. Genetics of Behavioral Traits and Diseases Room 6B #21-#24 11. New Frontiers in Computational Genomics Room 6C #25-#28 12. Bone and Muscle: Identifying Causal Genes Room 6D #29-#32 13. Precision Medicine Initiatives: Outcomes and Lessons Learned Room 6E #33-#36 14. Environmental Exposures in Human Traits Room 6F #37-#40 Wednesday, October 17, 4:15-5:45 pm, Concurrent Platform Session B: 24. Variant Interpretation Practices and Resources Ballroom 20A #41-#46 25. Integrated Variant Analysis in Cancer Genomics Ballroom 20BC #47-#52 26. Gene Discovery and Functional Models of Neurological Disorders Ballroom 20D #53-#58 27. Whole Exome and Whole Genome Associations Room 6A #59-#64 28. Sequencing-based Diagnostics for Newborns and Infants Room 6B #65-#70 29. Omics Studies in Alzheimer's Disease Room 6C #71-#76 30. Cardiac, Valvular, and Vascular Disorders Room 6D #77-#82 31. Natural Selection and Human Phenotypes Room 6E #83-#88 32. Genetics of Cardiometabolic Traits Room 6F #89-#94 Wednesday, October 17, 6:00-7:00 pm, Concurrent Platform Session C: 33.
    [Show full text]